Lenalidomide Stada

Lenalidomide, the active ingredient in Lenalidomide Stada, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is employed in the treatment of certain blood cancers, specifically multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical and commercial use. Our distribution network ensures timely delivery across continents.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies. - Multiple myeloma: improves progression‑free survival when combined with dexamethasone. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. - Relapsed or refractory disease: offers an additional therapeutic option for patients whose disease has progressed after standard treatments.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels that may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Constipation: difficulty passing stools. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil counts requiring medical intervention. - Serious infections: opportunistic or bacterial infections requiring hospitalization. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease. - Hepatotoxicity: significant liver enzyme elevations or liver injury.

When prescribing lenalidomide, clinicians should observe several safety considerations. - Blood count monitoring: perform complete blood counts regularly to detect neutropenia or thrombocytopenia. - Thrombosis risk assessment: evaluate patient history and consider prophylactic anticoagulation when appropriate. - Pregnancy avoidance: the drug is contraindicated in pregnancy; ensure effective contraception. - Breastfeeding caution: advise against nursing while on therapy due to unknown excretion. - Renal function adjustment: modify dosing in patients with impaired renal clearance. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Live vaccines: reduced vaccine efficacy and potential infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): decrease lenalidomide plasma levels. - Other myelosuppressive agents: additive risk of severe cytopenias. - Diuretics: may affect renal clearance of lenalidomide.